Chemoradiotherapy with 3-weekly CDDP 80 mg/m2 for head and neck squamous cell carcinoma: 5-year survival data from a phase 2 study
ObjectiveThe global standard for chemoradiation therapy (CCRT) for head and neck squamous cell carcinoma is cisplatin 100 mg/m2 administered once every three weeks, although cisplatin 80 mg/m2 is also widely used as an alternative treatment to reduce adverse events in Japan. We aimed to assess the l...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-12-01
|
| Series: | Frontiers in Surgery |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fsurg.2022.1035349/full |
| _version_ | 1798005604970659840 |
|---|---|
| author | Kohei Otaki Takeshi Takahashi Ryoko Tanaka Kohei Saijo Jo Omata Yusuke Yokoyama Ryusuke Shodo Yushi Ueki Keisuke Yamazaki Hisayuki Ota Takafumi Togashi Nao Takahashi Ryuichi Okabe Hiroshi Matsuyama Arata Horii |
| author_facet | Kohei Otaki Takeshi Takahashi Ryoko Tanaka Kohei Saijo Jo Omata Yusuke Yokoyama Ryusuke Shodo Yushi Ueki Keisuke Yamazaki Hisayuki Ota Takafumi Togashi Nao Takahashi Ryuichi Okabe Hiroshi Matsuyama Arata Horii |
| author_sort | Kohei Otaki |
| collection | DOAJ |
| description | ObjectiveThe global standard for chemoradiation therapy (CCRT) for head and neck squamous cell carcinoma is cisplatin 100 mg/m2 administered once every three weeks, although cisplatin 80 mg/m2 is also widely used as an alternative treatment to reduce adverse events in Japan. We aimed to assess the long-term survival outcomes and late adverse events associated with CCRT with a 3-weekly cisplatin dose of 80 mg/m2.MethodsA phase 2 study on CCRT with a 3-weekly cisplatin dose of 80 mg/m2 was performed in 47 patients between April 2015 and December 2016 at four centers in Japan. Survival outcomes and late adverse events at 5 years after this phase 2 trial were investigated.ResultsThe median follow-up period was 61 months. The 5-year progression-free survival/overall survival of all 47 patients was 66.0%/76.6%, while that of patients with stage III, IV disease (UICC) was 65.6%/71.9%. Seventeen patients (36%) experienced dysphagia as a late adverse event. Univariate and multivariate analyses revealed a significant association between acute mucositis/low body mass index (BMI) during CCRT and late dysphagia.ConclusionThe survival outcomes of CCRT with a 3-weekly cisplatin dose of 80 mg/m2 may be comparable to the previously reported dose of 100 mg/m2. Acute mucositis and low BMI at CCRT were risk factors for late dysphagia, indicating the importance of managing these conditions during CCRT to prevent late adverse events. Caution and care for acute mucositis and swallowing training in patients with low BMI may be important for preventing late-stage dysphagia. |
| first_indexed | 2024-04-11T12:41:53Z |
| format | Article |
| id | doaj.art-52cac4a871764e5e9fbdb01d7c2fb654 |
| institution | Directory Open Access Journal |
| issn | 2296-875X |
| language | English |
| last_indexed | 2024-04-11T12:41:53Z |
| publishDate | 2022-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Surgery |
| spelling | doaj.art-52cac4a871764e5e9fbdb01d7c2fb6542022-12-22T04:23:27ZengFrontiers Media S.A.Frontiers in Surgery2296-875X2022-12-01910.3389/fsurg.2022.10353491035349Chemoradiotherapy with 3-weekly CDDP 80 mg/m2 for head and neck squamous cell carcinoma: 5-year survival data from a phase 2 studyKohei Otaki0Takeshi Takahashi1Ryoko Tanaka2Kohei Saijo3Jo Omata4Yusuke Yokoyama5Ryusuke Shodo6Yushi Ueki7Keisuke Yamazaki8Hisayuki Ota9Takafumi Togashi10Nao Takahashi11Ryuichi Okabe12Hiroshi Matsuyama13Arata Horii14Department of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, JapanDepartment of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, JapanDepartment of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, JapanDepartment of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, JapanDepartment of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, JapanDepartment of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, JapanDepartment of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, JapanDepartment of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, JapanDepartment of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, JapanDepartment of Head and Neck Surgery, Niigata Cancer Center Hospital, Niigata, JapanDepartment of Head and Neck Surgery, Niigata Cancer Center Hospital, Niigata, JapanDepartment of Otorhinolaryngology, Nagaoka Red Cross Hospital, Niigata, JapanDepartment of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, JapanDepartment of Otorhinolaryngology, Niigata City General Hospital, Niigata, JapanDepartment of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, JapanObjectiveThe global standard for chemoradiation therapy (CCRT) for head and neck squamous cell carcinoma is cisplatin 100 mg/m2 administered once every three weeks, although cisplatin 80 mg/m2 is also widely used as an alternative treatment to reduce adverse events in Japan. We aimed to assess the long-term survival outcomes and late adverse events associated with CCRT with a 3-weekly cisplatin dose of 80 mg/m2.MethodsA phase 2 study on CCRT with a 3-weekly cisplatin dose of 80 mg/m2 was performed in 47 patients between April 2015 and December 2016 at four centers in Japan. Survival outcomes and late adverse events at 5 years after this phase 2 trial were investigated.ResultsThe median follow-up period was 61 months. The 5-year progression-free survival/overall survival of all 47 patients was 66.0%/76.6%, while that of patients with stage III, IV disease (UICC) was 65.6%/71.9%. Seventeen patients (36%) experienced dysphagia as a late adverse event. Univariate and multivariate analyses revealed a significant association between acute mucositis/low body mass index (BMI) during CCRT and late dysphagia.ConclusionThe survival outcomes of CCRT with a 3-weekly cisplatin dose of 80 mg/m2 may be comparable to the previously reported dose of 100 mg/m2. Acute mucositis and low BMI at CCRT were risk factors for late dysphagia, indicating the importance of managing these conditions during CCRT to prevent late adverse events. Caution and care for acute mucositis and swallowing training in patients with low BMI may be important for preventing late-stage dysphagia.https://www.frontiersin.org/articles/10.3389/fsurg.2022.1035349/fullhead and neck cancersquamous cell carcinomachemoradiotherapy3-weekly CDDP 80 mg/m 25-year survival datalate adverse events |
| spellingShingle | Kohei Otaki Takeshi Takahashi Ryoko Tanaka Kohei Saijo Jo Omata Yusuke Yokoyama Ryusuke Shodo Yushi Ueki Keisuke Yamazaki Hisayuki Ota Takafumi Togashi Nao Takahashi Ryuichi Okabe Hiroshi Matsuyama Arata Horii Chemoradiotherapy with 3-weekly CDDP 80 mg/m2 for head and neck squamous cell carcinoma: 5-year survival data from a phase 2 study Frontiers in Surgery head and neck cancer squamous cell carcinoma chemoradiotherapy 3-weekly CDDP 80 mg/m 2 5-year survival data late adverse events |
| title | Chemoradiotherapy with 3-weekly CDDP 80 mg/m2 for head and neck squamous cell carcinoma: 5-year survival data from a phase 2 study |
| title_full | Chemoradiotherapy with 3-weekly CDDP 80 mg/m2 for head and neck squamous cell carcinoma: 5-year survival data from a phase 2 study |
| title_fullStr | Chemoradiotherapy with 3-weekly CDDP 80 mg/m2 for head and neck squamous cell carcinoma: 5-year survival data from a phase 2 study |
| title_full_unstemmed | Chemoradiotherapy with 3-weekly CDDP 80 mg/m2 for head and neck squamous cell carcinoma: 5-year survival data from a phase 2 study |
| title_short | Chemoradiotherapy with 3-weekly CDDP 80 mg/m2 for head and neck squamous cell carcinoma: 5-year survival data from a phase 2 study |
| title_sort | chemoradiotherapy with 3 weekly cddp 80 mg m2 for head and neck squamous cell carcinoma 5 year survival data from a phase 2 study |
| topic | head and neck cancer squamous cell carcinoma chemoradiotherapy 3-weekly CDDP 80 mg/m 2 5-year survival data late adverse events |
| url | https://www.frontiersin.org/articles/10.3389/fsurg.2022.1035349/full |
| work_keys_str_mv | AT koheiotaki chemoradiotherapywith3weeklycddp80mgm2forheadandnecksquamouscellcarcinoma5yearsurvivaldatafromaphase2study AT takeshitakahashi chemoradiotherapywith3weeklycddp80mgm2forheadandnecksquamouscellcarcinoma5yearsurvivaldatafromaphase2study AT ryokotanaka chemoradiotherapywith3weeklycddp80mgm2forheadandnecksquamouscellcarcinoma5yearsurvivaldatafromaphase2study AT koheisaijo chemoradiotherapywith3weeklycddp80mgm2forheadandnecksquamouscellcarcinoma5yearsurvivaldatafromaphase2study AT joomata chemoradiotherapywith3weeklycddp80mgm2forheadandnecksquamouscellcarcinoma5yearsurvivaldatafromaphase2study AT yusukeyokoyama chemoradiotherapywith3weeklycddp80mgm2forheadandnecksquamouscellcarcinoma5yearsurvivaldatafromaphase2study AT ryusukeshodo chemoradiotherapywith3weeklycddp80mgm2forheadandnecksquamouscellcarcinoma5yearsurvivaldatafromaphase2study AT yushiueki chemoradiotherapywith3weeklycddp80mgm2forheadandnecksquamouscellcarcinoma5yearsurvivaldatafromaphase2study AT keisukeyamazaki chemoradiotherapywith3weeklycddp80mgm2forheadandnecksquamouscellcarcinoma5yearsurvivaldatafromaphase2study AT hisayukiota chemoradiotherapywith3weeklycddp80mgm2forheadandnecksquamouscellcarcinoma5yearsurvivaldatafromaphase2study AT takafumitogashi chemoradiotherapywith3weeklycddp80mgm2forheadandnecksquamouscellcarcinoma5yearsurvivaldatafromaphase2study AT naotakahashi chemoradiotherapywith3weeklycddp80mgm2forheadandnecksquamouscellcarcinoma5yearsurvivaldatafromaphase2study AT ryuichiokabe chemoradiotherapywith3weeklycddp80mgm2forheadandnecksquamouscellcarcinoma5yearsurvivaldatafromaphase2study AT hiroshimatsuyama chemoradiotherapywith3weeklycddp80mgm2forheadandnecksquamouscellcarcinoma5yearsurvivaldatafromaphase2study AT aratahorii chemoradiotherapywith3weeklycddp80mgm2forheadandnecksquamouscellcarcinoma5yearsurvivaldatafromaphase2study |